A Comparison of 18F-FDG PET/CT and 68Ga-PSMA PET/CT in Detecting Osteonecrosis of the Jaw in a Patient With Prostate Cancer

Abstract

Abstract Medication-related osteonecrosis of the jaw (ONJ) is rare adverse effect of zoledronic acid. We present ONJ detected in a 65-year-old man with prostate cancer who underwent 18F-FDG PET/CT for metabolic characterization and to exclude a second primary malignancy of the liver lesion observed in 68Ga-PSMA PET/CT. ONJ has high metabolic activity on 18F-FDG PET/CT and no PSMA receptor activation on the 68Ga-PSMA PET/CT. In this case, we wanted to underline the importance of 18F-FDG PET/CT imaging of medication-related ONJ in patients receiving zoledronic acid therapy and to emphasize that rapid and appropriate treatment can be provided.